Insilico Medicine’s AI-originated IPF drug enters Phase 3, but the hardest test begins now
Find out how Insilico Medicine’s AI-originated rentosertib is entering Phase 3 testing for idiopathic pulmonary fibrosis.
Pharma & Biotech
Medical Devices & Diagnostics
QT Imaging passed its first FDA inspection cleanly, but can adoption follow?
Find out how QT Imaging’s clean FDA inspection could support Breast Acoustic CT scale-up and breast imaging adoption.
Pharma & Biotech
Pharvaris has an FDA review date for deucrictibant, but can it stand out?
Find out how Pharvaris’ deucrictibant could reshape oral treatment options for hereditary angioedema attacks.
Medical Devices & Diagnostics
Presage Technologies SmartSpectra cleared for contactless vital signs monitoring
Find out how Presage Technologies’ SmartSpectra software uses phone cameras to measure pulse and breathing rate without sensors.
Pharma & Biotech
Can CoRegen’s CRG-150 turn regulatory T cells into a solid tumour weapon?
Find out how CoRegen is advancing CRG-150 into human trials for metastatic breast cancer, prostate cancer and solid tumours.
Medical Devices & Diagnostics
Can Movmedix turn LARS ACJ clearance into meaningful United States adoption?
Find out how Movmedix plans to launch its FDA-cleared LARS ACJ synthetic ligament system for severe shoulder joint injuries.
Pharma & Biotech
LTZ Therapeutics secures FDA clearance for LTZ-232 Phase 1 cancer trial
Find out how LTZ Therapeutics is advancing LTZ-232 into a Phase 1 trial targeting macrophages in metastatic colorectal cancer.
Medical Devices & Diagnostics
Can CyPath Lung sales growth turn bioAffinity Technologies into a viable diagnostics company?
Discover how bioAffinity Technologies’ CyPath Lung test is gaining physician adoption while clinical, reimbursement and funding risks remain.
Medical Devices & Diagnostics
How the Cepheid Xpert Xpress MVP test could improve vaginal infection diagnosis
Discover how Cepheid’s Xpert Xpress MVP test delivers rapid PCR results for bacterial vaginosis, candidiasis and trichomoniasis in one visit.
Pharma & Biotech
Kailera advances oral GLP-1 strategy after positive obesity and diabetes Phase 3 trials
Kailera Therapeutics has reported positive Phase 3 results for oral GLP-1 candidate KAI-7535 in obesity and type 2 diabetes, although high gastrointestinal event rates remain a major commercial and clinical concern.